XML 29 R19.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2025202420252024
Customer A24 %20 %23 %24 %
Customer B21 %22 %19 %21 %
Customer C**10 %*

Accounts Receivable, Net
 September 30, 2025December 31, 2024
Customer A14 %13 %
Customer B17 %25 %
Customer C16 %*
*Less than 10%.
Schedule of Disaggregation of Revenue
The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2025202420252024
Revenue:
Commercial$9,454 $6,779 $27,025 $22,314 
Government3,988 2,633 11,621 10,276 
Client direct bill(1)3,733 2,981 11,100 9,175 
Other(2)69 114 198 221 
Total revenue$17,244 $12,507 $49,944 $41,986 
(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay.
Schedule of Cash and Cash Equivalents
Cash, cash equivalents, and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):
 
 September 30, 2025December 31, 2024
Cash and cash equivalents$35,652 $22,036 
Restricted cash200 200 
Total cash, cash equivalents and restricted cash$35,852 $22,236 
Schedule of Restricted Cash and Cash Equivalents
Cash, cash equivalents, and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):
 
 September 30, 2025December 31, 2024
Cash and cash equivalents$35,652 $22,036 
Restricted cash200 200 
Total cash, cash equivalents and restricted cash$35,852 $22,236 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):
 
 September 30, 2025September 30, 2024
Warrants to purchase common stock580,339 325,330 
Common stock options526,889 576,151 
Restricted stock units1,764,912 1,810,468 
Employee stock purchase plan8,219 12,570 
Total2,880,359 2,724,519